Written by the Nuvirox Research Team
Key Points
- There is no published human clinical trial testing NAD+ precursors for stroke recovery — every finding below comes from mouse or rat models.
- In those animal models, boosting NAD+ has reduced brain injury, calmed post-stroke inflammation, and improved movement recovery.
- Aging worsens post-stroke inflammation in mice, and NAD+ restoration reversed some of that age-related effect — a finding that has not been tested in older human stroke patients.
Short answer: there is no published human trial of NAD+ precursors for stroke recovery. Everything currently known comes from rodent models. That's an important thing to say plainly before going any further, because it changes what this article can responsibly offer.
Why is NAD+ even discussed in the context of stroke?
During an ischemic stroke, blocked blood flow triggers a cascade — energy failure, oxidative stress, inflammation, and cell death — that continues to unfold over hours and days after the initial event. NAD+ is central to several of the systems involved in that cascade: it fuels mitochondrial ATP production, and it's consumed by PARP enzymes that respond to DNA damage. In animal studies, NAD+ levels drop sharply in the brain after a stroke, which is part of why researchers have investigated whether restoring it might limit damage or support recovery.
What has actually been shown — in animals
A 2025 study in Journal of Neuroinflammation found that aging worsens post-stroke inflammation in mice partly through changes in circulating immune cell (monocyte) metabolism, and that restoring NAD+ with nicotinamide riboside corrected some of that metabolic dysfunction, reduced neuroinflammatory signaling, and improved functional recovery — specifically in aged mice, which the researchers note are more representative of the human stroke population than young mice used in earlier work. Separately, intranasal NAD+ administration reduced brain injury in a rat model of transient focal ischemia, and nicotinamide mononucleotide (NMN) protected blood-brain barrier integrity in a mouse model of stroke treatment complications. A related study found that boosting the NAD+-generating enzyme pathway (Nampt) promoted new neuron growth after stroke in mice, even when treatment started later than the acute window.
A related line of CNS-injury research
A separate but mechanistically related body of work has looked at NAD+ restoration after spinal cord injury (SCI) — a different kind of acute central nervous system injury, but one that shares some of the same secondary damage cascade as stroke: energy failure, oxidative stress, and progressive tissue damage in the hours to weeks after the initial event. In a rat model of thoracic spinal cord contusion injury, researchers found that administering nicotinamide riboside enhanced NAD+ levels within the injured spinal cord tissue, reduced tissue damage, and improved locomotor recovery. The researchers describe NR as safe and effective at reaching the injured tissue and modifying its biochemistry in this model. This isn't stroke research, and spinal cord injury and ischemic stroke differ in important ways (mechanical trauma vs. blood-flow blockage, for instance), but it does reinforce that the broader "restore NAD+ after acute CNS injury" hypothesis has more than one line of animal evidence behind it — all still awaiting human confirmation across every condition it's been tested in.
What this doesn't tell you
None of this has been tested in a person who has had a stroke. Rodent ischemia models, however well-designed, don't capture the full complexity of human strokes — variable location, size, underlying cause (clot vs. bleed), age, comorbidities, and the medications already used in acute stroke care (like clot-dissolving drugs, which have their own interactions with the same biological pathways NAD+ touches). There is no established human dose, no safety data specific to the acute or subacute post-stroke period, and no evidence about how NAD+ precursors interact with standard stroke treatments or rehabilitation.
What stroke recovery actually depends on
Stroke recovery outcomes are driven overwhelmingly by time-to-treatment in the acute phase, the specific brain regions affected, and structured rehabilitation — physical, occupational, and speech therapy — in the weeks and months after. None of that is optional or substitutable. If you or someone you love is recovering from a stroke, the people who should be shaping that recovery plan are your neurologist and rehabilitation team, not a supplement aisle.
A note on this topic: Because there is no human evidence base here at all — positive or negative — we are not positioning NAD+ Restore as relevant to stroke recovery. If you're researching this for yourself or a family member, the right next step is a conversation with the treating neurology or rehabilitation team.
For related, better-studied territory, our review of NAD+ and circulation covers a real human trial in peripheral artery disease, and NAD+ and cardiovascular health looks at the broader vascular research landscape, both of which have actual human RCT data behind them.
Frequently asked questions
Has NAD+ been tested in human stroke patients at all?
Not as a treatment for stroke recovery, no. All current evidence — reduced brain injury, less inflammation, improved movement recovery — comes from mouse and rat models.
Is it dangerous to take an NAD+ supplement after a stroke?
There's no dedicated safety data for the post-stroke period specifically, including potential interactions with acute stroke medications. This is a question to raise directly with the treating physician, not to decide independently.
Why do researchers keep studying NAD+ for stroke if there's no human data yet?
The mechanistic rationale — energy failure and DNA-repair demand after ischemia — is genuinely strong, and the mouse data is consistently positive across several independent labs. That's exactly the profile that justifies moving toward human trials, which simply haven't happened yet for this specific condition.
What actually helps stroke recovery today?
Time-to-treatment in the acute phase and structured rehabilitation (physical, occupational, and speech therapy) remain the evidence-backed foundations of stroke recovery, guided by a neurology and rehab team.
Is spinal cord injury research the same as stroke research?
No — they're related lines of central nervous system injury research sharing some biological overlap (energy failure, oxidative stress after acute injury), but spinal cord injury and ischemic stroke are distinct conditions, and a finding in one animal model doesn't establish the same effect in the other.
Does aging change how NAD+ affects stroke outcomes?
In the 2025 mouse study, the NAD+-related recovery benefit was specifically studied in aged mice, and the researchers noted this matters because most human stroke patients are older — a detail that at least makes the model more relevant to the real-world population, even though it remains a mouse study.
What would need to happen before this became relevant to actual patients?
A registered human clinical trial specifically in stroke patients, with safety data covering the acute and subacute recovery periods and any interactions with standard stroke medications, would need to be conducted and published before this moved from animal research to a genuine clinical option.
The bottom line: this is one of the clearer cases where the honest answer is "we don't know yet, in humans" rather than a hedge. The mechanism is interesting; the mouse data is consistent; the human evidence simply doesn't exist. That gap deserves to be stated directly rather than talked around.
References
- Chen J, et al. NAD+ depletion drives age-related monocyte hyperinflammation after stroke and is reversed by nicotinamide riboside. J Neuroinflammation. 2025. DOI: 10.1186/s12974-025-03638-6.
- Wei CC, Kong YY, Hua X, et al. NAD replenishment with nicotinamide mononucleotide protects blood-brain barrier integrity and attenuates delayed tissue plasminogen activator-induced haemorrhagic transformation after cerebral ischaemia. Br J Pharmacol. 2017;174:3823-3836.
- Zheng C, Han J, Xia W, et al. Intranasal administration with NAD+ profoundly decreases brain injury in a rat model of transient focal ischemia. Front Biosci. 2007;12:2728-2734.
- Regenerative Neurogenesis After Ischemic Stroke Promoted by Nicotinamide Phosphoribosyltransferase-Nicotinamide Adenine Dinucleotide Cascade. Stroke. PMID: 26060246.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.